ICD-10: C85.87

Other specified types of non-Hodgkin lymphoma, spleen

Additional Information

Approximate Synonyms

ICD-10 code C85.87 refers to "Other specified types of non-Hodgkin lymphoma, spleen." This classification encompasses various forms of non-Hodgkin lymphoma (NHL) that do not fall under more specific categories but are nonetheless significant in clinical practice. Below are alternative names and related terms associated with this code.

Alternative Names for C85.87

  1. Non-Hodgkin Lymphoma, Spleen: This is a straightforward alternative name that directly indicates the involvement of the spleen in non-Hodgkin lymphoma.

  2. Spleen-Localized Non-Hodgkin Lymphoma: This term emphasizes the localization of the lymphoma to the spleen, distinguishing it from other forms that may affect different lymphatic tissues.

  3. Splenic Lymphoma: While this term can refer to various types of lymphomas affecting the spleen, it is often used interchangeably with non-Hodgkin lymphoma when the context is clear.

  4. Other Specified Non-Hodgkin Lymphoma: This term highlights that the lymphoma is a type of non-Hodgkin lymphoma that does not fit into the more commonly recognized categories.

  1. Lymphoproliferative Disorders: This broader category includes various conditions characterized by the proliferation of lymphocytes, including non-Hodgkin lymphoma.

  2. B-cell Lymphoma: Many non-Hodgkin lymphomas are of B-cell origin, and this term may be relevant when discussing specific types that could be classified under C85.87.

  3. T-cell Lymphoma: Similar to B-cell lymphoma, this term refers to non-Hodgkin lymphomas that arise from T-cells, which may also be included under the broader classification of C85.87.

  4. Splenic Marginal Zone Lymphoma: While this is a specific type of non-Hodgkin lymphoma, it may be relevant in discussions about other specified types affecting the spleen.

  5. Primary Splenic Lymphoma: This term is used to describe lymphomas that originate in the spleen, which may include various subtypes classified under C85.87.

  6. Lymphoma of the Spleen: A general term that can refer to any lymphoma affecting the spleen, including both Hodgkin and non-Hodgkin types.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C85.87 is crucial for accurate diagnosis, treatment planning, and coding in clinical settings. These terms help healthcare professionals communicate effectively about the specific types of non-Hodgkin lymphoma that may affect the spleen, ensuring that patients receive appropriate care tailored to their condition. If you need further details or specific examples of non-Hodgkin lymphoma types, feel free to ask!

Treatment Guidelines

When addressing the standard treatment approaches for ICD-10 code C85.87, which refers to "Other specified types of non-Hodgkin lymphoma, spleen," it is essential to understand the broader context of non-Hodgkin lymphoma (NHL) and the specific characteristics of the lymphoma affecting the spleen.

Overview of Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma encompasses a diverse group of blood cancers that originate in the lymphatic system. The classification of NHL is based on various factors, including the type of lymphocyte involved (B-cell or T-cell), the growth rate of the cancer (indolent or aggressive), and specific genetic markers. The spleen can be involved in various types of NHL, and treatment approaches may vary based on the specific subtype and stage of the disease.

Standard Treatment Approaches

1. Chemotherapy

Chemotherapy remains a cornerstone of treatment for many types of non-Hodgkin lymphoma, including those affecting the spleen. Common regimens may include:

  • CHOP: Cyclophosphamide, doxorubicin, vincristine, and prednisone, often used for aggressive B-cell lymphomas.
  • R-CHOP: The addition of rituximab (a monoclonal antibody) to the CHOP regimen, which has shown improved outcomes in B-cell lymphomas.

2. Targeted Therapy

Targeted therapies have become increasingly important in the treatment of NHL. For example:

  • Rituximab: This monoclonal antibody targets CD20 on B-cells and is commonly used in various B-cell lymphomas, including those that may involve the spleen.
  • Brentuximab vedotin: This is used for specific types of T-cell lymphomas and may be considered based on the lymphoma subtype.

3. Radiation Therapy

Radiation therapy may be utilized in certain cases, particularly for localized disease or as a palliative measure to relieve symptoms. It can be effective in targeting splenic involvement when the disease is confined to that area.

4. Hematopoietic Stem Cell Transplantation (HSCT)

For patients with aggressive forms of NHL or those who have relapsed after initial treatment, hematopoietic stem cell transplantation may be considered. This approach can be particularly beneficial for younger patients or those with a good performance status.

5. Clinical Trials

Participation in clinical trials may provide access to novel therapies and treatment strategies that are not yet widely available. Patients with C85.87 may benefit from emerging treatments that target specific genetic mutations or pathways involved in their lymphoma.

Considerations for Treatment

The choice of treatment for non-Hodgkin lymphoma involving the spleen is influenced by several factors:

  • Subtype of NHL: Different subtypes may respond better to specific therapies.
  • Stage of Disease: Early-stage disease may be treated differently than advanced-stage disease.
  • Patient Factors: Age, overall health, and comorbid conditions can impact treatment decisions.

Conclusion

In summary, the treatment of non-Hodgkin lymphoma affecting the spleen (ICD-10 code C85.87) typically involves a combination of chemotherapy, targeted therapies, radiation, and potentially stem cell transplantation, depending on the specific characteristics of the lymphoma and the patient's overall health. Ongoing research and clinical trials continue to shape the landscape of treatment options, offering hope for improved outcomes in patients with this complex disease. For personalized treatment plans, consultation with a hematologist or oncologist specializing in lymphomas is essential.

Description

ICD-10 code C85.87 refers to "Other specified types of non-Hodgkin lymphoma, spleen." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system. Below is a detailed overview of this condition, including its clinical description, characteristics, and relevant considerations.

Clinical Description of C85.87

Definition and Classification

Non-Hodgkin lymphoma is a heterogeneous group of malignancies that arise from lymphocytes, primarily B-cells and T-cells. The term "other specified types" indicates that the lymphoma does not fit neatly into the more commonly recognized subtypes, such as diffuse large B-cell lymphoma or follicular lymphoma. Instead, C85.87 is used for cases that may have unique histological features or clinical presentations that warrant specific attention.

Spleen Involvement

When non-Hodgkin lymphoma affects the spleen, it can lead to splenomegaly (enlargement of the spleen), which may be detected during physical examinations or imaging studies. The spleen plays a crucial role in filtering blood and supporting the immune system, and its involvement in lymphoma can significantly impact a patient's overall health and treatment options.

Symptoms

Patients with C85.87 may present with a variety of symptoms, including:
- Abdominal pain or discomfort: Often due to splenomegaly.
- Fatigue: Common in many types of cancer due to anemia or the body's response to malignancy.
- Unexplained weight loss: A frequent symptom in lymphoma patients.
- Fever and night sweats: Indicative of systemic involvement.
- Lymphadenopathy: Swelling of lymph nodes, which may or may not be present.

Diagnosis

Diagnosis typically involves a combination of:
- Imaging studies: Such as ultrasound, CT scans, or MRI to assess spleen size and detect any masses.
- Biopsy: A definitive diagnosis often requires a biopsy of the spleen or affected lymph nodes to determine the specific type of lymphoma.
- Blood tests: To evaluate overall health, blood cell counts, and potential organ function.

Treatment Options

Treatment for non-Hodgkin lymphoma, including cases coded as C85.87, may vary based on the specific characteristics of the lymphoma and the patient's overall health. Common treatment modalities include:
- Chemotherapy: Often the first line of treatment for aggressive forms of NHL.
- Radiation therapy: May be used in localized cases or as a palliative measure.
- Targeted therapies: Such as monoclonal antibodies (e.g., Rituximab) that specifically target cancer cells.
- Stem cell transplant: Considered for eligible patients with relapsed or refractory disease.

Prognosis

The prognosis for patients with C85.87 can vary widely based on several factors, including the specific subtype of lymphoma, the stage at diagnosis, and the patient's response to treatment. Generally, early detection and appropriate treatment can lead to better outcomes.

Conclusion

ICD-10 code C85.87 captures a specific category of non-Hodgkin lymphoma that affects the spleen, highlighting the importance of accurate diagnosis and tailored treatment strategies. Understanding the clinical features, diagnostic approaches, and treatment options is essential for healthcare providers managing patients with this condition. As research continues to evolve, new therapies and insights into the biology of non-Hodgkin lymphoma may further enhance patient care and outcomes.

Clinical Information

ICD-10 code C85.87 refers to "Other specified types of non-Hodgkin lymphoma, spleen." Non-Hodgkin lymphoma (NHL) encompasses a diverse group of blood cancers that originate in the lymphatic system, and the clinical presentation can vary significantly based on the specific type and location of the lymphoma. Below is a detailed overview of the clinical presentation, signs, symptoms, and patient characteristics associated with this diagnosis.

Clinical Presentation

General Characteristics of Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma can present in various forms, and the spleen is one of the common sites for involvement. The clinical presentation often includes:

  • Lymphadenopathy: Swelling of lymph nodes, which may be localized or generalized.
  • Splenomegaly: Enlargement of the spleen, which can be detected during a physical examination or imaging studies.
  • B Symptoms: These are systemic symptoms that may include:
  • Fever
  • Night sweats
  • Unexplained weight loss

Specific Signs and Symptoms

Patients with C85.87 may exhibit a range of signs and symptoms, including:

  • Abdominal Pain or Discomfort: Due to splenomegaly or lymphadenopathy affecting abdominal organs.
  • Fatigue: A common symptom due to anemia or the body's response to cancer.
  • Anemia: Resulting from bone marrow involvement or splenic sequestration of blood cells.
  • Increased Infections: Patients may experience recurrent infections due to compromised immune function.

Patient Characteristics

Demographics

  • Age: Non-Hodgkin lymphoma can occur at any age, but the risk increases with age, particularly in individuals over 60.
  • Gender: Some types of NHL are more common in males than females, although this can vary by subtype.

Risk Factors

Several risk factors may predispose individuals to develop non-Hodgkin lymphoma, including:

  • Immunosuppression: Conditions such as HIV/AIDS, organ transplantation, or autoimmune diseases can increase the risk.
  • Family History: A family history of lymphoma or other hematologic malignancies may elevate risk.
  • Environmental Exposures: Certain chemicals, pesticides, and previous radiation exposure have been linked to NHL.

Comorbidities

Patients with C85.87 may also have comorbid conditions that can complicate their clinical picture, such as:

  • Chronic Infections: Such as hepatitis or HIV, which can influence the immune system.
  • Other Hematologic Disorders: Conditions like myelodysplastic syndromes or chronic lymphocytic leukemia may coexist.

Conclusion

The clinical presentation of non-Hodgkin lymphoma, particularly for the subtype coded as C85.87, is characterized by a variety of symptoms and signs that reflect the disease's systemic nature and its impact on the lymphatic system and spleen. Understanding these characteristics is crucial for timely diagnosis and management. If you suspect non-Hodgkin lymphoma, it is essential to conduct a thorough clinical evaluation, including imaging and possibly biopsy, to confirm the diagnosis and determine the appropriate treatment plan.

Diagnostic Criteria

The diagnosis of non-Hodgkin lymphoma (NHL), specifically under the ICD-10 code C85.87 for "Other specified types of non-Hodgkin lymphoma, spleen," involves a comprehensive evaluation that includes clinical, laboratory, and imaging assessments. Below is a detailed overview of the criteria and processes typically used in diagnosing this condition.

Clinical Evaluation

Symptoms

Patients may present with a variety of symptoms that can suggest the presence of non-Hodgkin lymphoma, including:
- Lymphadenopathy: Swelling of lymph nodes, which may be painless.
- Splenomegaly: Enlargement of the spleen, which can be detected during a physical examination.
- B Symptoms: These include fever, night sweats, and unexplained weight loss, which are often associated with lymphoproliferative disorders.

Medical History

A thorough medical history is essential, including:
- Previous diagnoses of lymphoma or other hematologic malignancies.
- Family history of lymphomas or related conditions.
- Exposure to risk factors such as certain infections (e.g., Epstein-Barr virus) or environmental toxins.

Laboratory Tests

Blood Tests

  • Complete Blood Count (CBC): This test can reveal anemia, thrombocytopenia, or leukopenia, which may indicate bone marrow involvement.
  • Lactate Dehydrogenase (LDH): Elevated levels can suggest aggressive disease or high tumor burden.

Bone Marrow Biopsy

A bone marrow biopsy may be performed to assess for the infiltration of lymphoma cells, especially if there is suspicion of bone marrow involvement.

Imaging Studies

Ultrasound and CT Scans

  • Ultrasound: Can help visualize splenomegaly and assess the structure of the spleen.
  • CT Scan: A computed tomography scan of the abdomen and pelvis is often used to evaluate the extent of disease, including lymph node involvement and splenic enlargement.

PET Scan

A positron emission tomography (PET) scan may be utilized to assess metabolic activity in lymph nodes and the spleen, helping to differentiate between active disease and residual masses post-treatment.

Histopathological Examination

Biopsy

A definitive diagnosis of non-Hodgkin lymphoma typically requires a biopsy of the affected lymph node or spleen tissue. The biopsy specimen is examined microscopically to identify:
- Cell Type: Determining whether the lymphoma is B-cell or T-cell in origin.
- Histological Subtype: Identifying the specific subtype of non-Hodgkin lymphoma, which is crucial for treatment planning.

Immunophenotyping

Flow cytometry or immunohistochemistry is used to analyze the surface markers on the lymphoma cells, aiding in the classification of the lymphoma and confirming the diagnosis.

Conclusion

The diagnosis of non-Hodgkin lymphoma, particularly for the ICD-10 code C85.87, involves a multifaceted approach that includes clinical evaluation, laboratory tests, imaging studies, and histopathological examination. Each of these components plays a critical role in accurately diagnosing the specific type of lymphoma and determining the appropriate treatment strategy. If you have further questions or need more specific information regarding treatment options or prognosis, feel free to ask!

Related Information

Approximate Synonyms

  • Non-Hodgkin Lymphoma Spleen
  • Spleen-Localized Non-Hodgkin Lymphoma
  • Splenic Lymphoma
  • Other Specified Non-Hodgkin Lymphoma
  • Lymphoproliferative Disorders
  • B-cell Lymphoma
  • T-cell Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Primary Splenic Lymphoma
  • Lymphoma of the Spleen

Treatment Guidelines

  • Chemotherapy is cornerstone of treatment
  • CHOP and R-CHOP are common regimens
  • Targeted therapy with rituximab is effective
  • Radiation therapy relieves localized symptoms
  • HSCT for aggressive or relapsed disease
  • Clinical trials provide access to emerging therapies

Description

  • Non-Hodgkin lymphoma
  • Diverse group of blood cancers
  • Arises from lymphocytes
  • Primarily B-cells and T-cells
  • Splenomegaly due to spleen involvement
  • Abdominal pain or discomfort
  • Fatigue is common symptom
  • Unexplained weight loss
  • Fever and night sweats indicative of systemic involvement
  • Lymphadenopathy swelling of lymph nodes

Clinical Information

  • Lymphadenopathy swelling of lymph nodes
  • Splenomegaly enlargement of spleen detected
  • Fever unexplained high temperature
  • Night sweats frequent sweating at night
  • Unexplained weight loss significant weight reduction
  • Abdominal pain due to splenomegaly or lymphadenopathy
  • Fatigue common symptom due to anemia or cancer
  • Anemia due to bone marrow involvement or blood cell sequestration
  • Increased infections recurrent due to compromised immune function

Diagnostic Criteria

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.